Here is the design of a clinical trial:

Official Title: The Efficacy of Transcranial Alternating Current Stimulation for Treating Post-stroke Depression: a Randomized Controlled Trial

Included conditions:
- Post-stroke Depression

Study Armgroups:
- {'label': 'NEXALIN Stimulator Group', 'type': 'EXPERIMENTAL', 'description': 'In this study, the group is the treatment group. Patients are randomly assigned to participate, and patients will be given current parameters for setting time and flow.', 'interventionNames': ['Device: NEXALIN ADI AC stimulator']}
- {'label': 'Pseudo-Stimulator Group', 'type': 'SHAM_COMPARATOR', 'description': 'In this study, the group is the control group. Patients are randomly assigned to participate, and patients will be given simulated electrical stimulation.', 'interventionNames': ['Device: Pseudo-stimulator']}

Interventions:
- {'type': 'DEVICE', 'name': 'NEXALIN ADI AC stimulator', 'description': "When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. The three electrodes are placed in this way to enhance the performance of the Nexalin ADI device. When the device is activated, there will be a weak current passing through the forehead electrode and each mastoid electrode. The current intensity of Nexalin ADI treatment defaults to 15.00 mA and the duration defaults to 40 minutes. Both are preset to default parameters and cannot be changed.", 'armGroupLabels': ['NEXALIN Stimulator Group']}
- {'type': 'DEVICE', 'name': 'Pseudo-stimulator', 'description': "When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. When the device is started, no current flows through the electrodes, but the instrument's operating procedures, parameter displays, and prompts are the same as for a real instrument.", 'armGroupLabels': ['Pseudo-Stimulator Group']}

Primary Outcomes:
- {'measure': 'the proportion of participants having an improvement at week 8', 'description': 'the proportion of participants having an improvement at week 8, which includes response per the Hamilton Depression Rating Scale 17-Item (HAMD-17) defined as a ≥ 50% reduction from the baseline or clinical recovery (score ≤ 7).', 'timeFrame': 'week 8'}

Please estimate the sample size based on the assumption: 
80% power, 2-tailed α level of 5%, 20% attrition rate
2.13
        Sample size calculation
        The sample size is estimated by assuming a 50% improvement rate at the end of 8 weeks in the active group and a 15% in the sham group, which were based on our pilot trial of the effect of tACS in adults with major depression disorder.[38] Thus, each group will be recommended to have a minimum sample size of 26 with a power to 80% and a 2-tailed Î± level of 5%.[53] Considering the 20% attrition rate, 32 evaluable participants will be required for each group. And the total sample size will be 70.